Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma
| Autor: | Eugster, Philippe J, Maurer, Jonathan, Vocat, Céline, Abid, Karim, Matter, Maurice, Wuerzner, Grégoire, Trepp, Roman, Fischli, Stefan, Henzen, Christoph, Kolb, Walter, Bilz, Stefan, Sigrist, Sarah, Beuschlein, Felix, Nölting, Svenja, Reul, Astrid, Schütze, Ina, Hubers, Scott A, Brown, Nancy J, Grouzmann, Eric |
|---|---|
| Přispěvatelé: | University of Zurich, Eugster, Philippe J |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
1303 Biochemistry
Biochemistry (medical) Clinical Biochemistry 10265 Clinic for Endocrinology and Diabetology Adrenal Gland Neoplasms 610 Medicine & health General Medicine Pheochromocytoma Adrenal Gland Neoplasms/diagnosis Healthy Volunteers Humans Metanephrine Neuropeptide Y/metabolism Paraganglioma/diagnosis Pheochromocytoma/diagnosis Protein Precursors Tandem Mass Spectrometry Mass spectrometry Metabolism Neuropeptide Y Paraganglioma Proneuropeptide Y Secretion c-flanking peptide of neuropeptide Y 1308 Clinical Biochemistry 2704 Biochemistry (medical) Biochemistry |
| Zdroj: | Clinica chimica acta; international journal of clinical chemistry, vol. 534, pp. 146-155 Eugster, Philippe J; Maurer, Jonathan; Vocat, Céline; Abid, Karim; Matter, Maurice; Wuerzner, Grégoire; Trepp, Roman; Fischli, Stefan; Henzen, Christoph; Kolb, Walter; Bilz, Stefan; Sigrist, Sarah; Beuschlein, Felix; Nölting, Svenja; Reul, Astrid; Schütze, Ina; Hubers, Scott A; Brown, Nancy J; Grouzmann, Eric (2022). Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. Clinica chimica acta, 534, pp. 146-155. Elsevier 10.1016/j.cca.2022.07.018 |
| Popis: | Neuropeptide Y (NPY1-36) is a vasoconstrictor peptide co-secreted with catecholamines by sympathetic nerves, the adrenal medulla, and neoplasms such as pheochromocytomas and paragangliomas (PPGLs). It is produced by the intracellular cleavage of proNPY and metabolized into multiple fragments with distinct biological activities. NPY immunoassays for PPGL have a diagnostic sensitivity ranging from 33 to 100%, depending on the antibody used. We have validated a multiplex micro-UHPLC-MS/MS assay for the specific and sensitive quantification of proNPY, NPY1-39, NPY1-37, NPY1-36, NPY2-36, NPY3-36, NPY1-35, NPY3-35, and the C-flanking peptide of NPY (CPON) (collectively termed NPYs), and determined the NPYs reference intervals and concentrations in 32 PPGL patients before, during, and after surgery. Depending on the peptide measured, NPYs were above the upper reference limit (URL) in 20% to 67% of patients, whereas plasma free metanephrine and normetanephrine, the gold standard for PPGL, were above the URL in 40% and 87% of patients, respectively. Age, sex, tachycardia, and tumor localization were not correlated with NPYs. Plasma free metanephrines performed better than NPYs in the detection of PPGL, but NPYs may be a substitute for an early diagnosis of PPGL for patients that suffer from severe kidney impairment or receiving treatments that interfere with catecholamine reuptake. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|